Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efdamrofusp alfa - Innovent Biologics

Next Previous
Search
Drug Profile

Efdamrofusp alfa - Innovent Biologics

Alternative Names: IBI-302

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AP Biosciences
  • Developer Innovent Biologics
  • Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Complement activation inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Suspended Diabetic macular oedema
  • Discontinued Solid tumours

Most Recent Events

  • 27 Mar 2025 Innovent Biologics plans a phase II trial for Diabetic macular oedema(Treatment-naive) in China (Intravitreal, Injection) in April 2025 (NCT06908876)
  • 13 May 2024 Innovent Biologics completes a phase II trial in Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreal) (NCT05403749)
  • 19 Mar 2024 Efficacy and adverse events data from a phase II trial in Wet age-related macular degeneration released by Innovent Biologics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top